Sun Pharma discontinue development of SCD-044 drug after trial disappointment
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
Subscribe To Our Newsletter & Stay Updated